Theseus Pharmaceuticals (THRX) Appoints Don Hayden to its Board
- World stocks skid as consumer data flashes recession worry
- S&P 500 Could Rally Almost 10% From Here, Bank of America's Suttmeier Suggests
- JPMorgan Reiterates Amazon, Booking, and Uber as Top Internet Stocks to Own
- Pinterest (PINS) CEO Silbermann Is Stepping Down, Shares Gain 8%
- Morgan Stanley Downgrades Upstart to Underweight, Price Target Cut by Nearly 80%
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) today announced the appointment of Don Hayden to its Board of Directors.
"We are thrilled to welcome Don as a tremendous addition to the Theseus Board. Don is a recognized, deeply experienced leader in the industry, and he will bring a unique perspective to Theseus as we advance our Phase 1/2 clinical trial of THE-630 in patients with GIST and expect to file an IND for our second program in EGFR-driven non-small cell lung cancer in 2023," said Tim Clackson, Ph.D., President and Chief Executive Officer of Theseus. "Don is an industry veteran with a record of success as an executive at large pharmaceutical companies, as well as board and board chair experience at multiple biopharmaceutical companies. We are sure to benefit from his knowledge and insights as we accelerate our clinical portfolio."
Mr. Hayden has over 40 years of experience in the life sciences industry, having served in numerous strategic leadership positions during his 25-year career at Bristol Myers-Squibb Company (BMS), including roles as President of Oncology and Immunology and as President of Global Pharmaceuticals. Following BMS, Mr. Hayden has served as Chair at REGENXBIO, Amicus Therapeutics, Insmed, Vitae Pharmaceuticals, and Gloucester Pharmaceuticals, among others, across which he provided strategic guidance through a variety of corporate milestones, including business combinations, financings, IPOs, and bringing approved therapies to market. More recently, Mr. Hayden served as Chair and CEO of oncology cell therapy developer, WindMIL Therapeutics. In addition to his new role at Theseus, Mr. Hayden also currently serves as Chair of Otsuka America Pharmaceuticals Incorporated. He holds an M.B.A from Indiana University and undergraduate degree from Harvard University.
Mr. Hayden added, "Theseus has an exceptional leadership team, with substantial success in targeted oncology, and shows immense potential to combat cancer treatment resistance with its pan-variant approach to targeted therapy. I look forward to supporting the Company's continued growth and clinical development, as it seeks to translate the power of its unique science into significant benefits for cancer patients."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Despegar.com Corp. (DESP) Appoints Dirk Donath to its Board
- FreightCar America (RAIL) Appoints Rodger L. Boehm, Jose De Nigris, and Travis D. Kelly to its Board
- Archer Aviation (ACHR) On Pace to Achieve Transition Flight By Year End
Create E-mail Alert Related CategoriesBoard Changes, Corporate News
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!